325

Любые общие механизмы при РАС и желудочно-кишечных заболеваний не предлагаются в публикациях, поэтому последнее упоминание может быть предрасполагающим фактором. Предыдущие исследования при РАС, в принципе, предположили клеточно-опосредованную активацию иммунного ответа - распространенную для слизистой оболочки, оно имеет патогенетический смысл, но рано интерпретировать это как этиологию. Используются различные методы лечения, но терапия не является окончательной при РАС. Системные препараты можно попробовать, если местная терапия неэффективна. На самом деле этиология и патогенез рецидивирующего афтозного стоматита актуальна

  • Internet ҳавола
  • DOI10.26739/2181-9297-2018-3-6
  • UzSCI тизимида яратилган сана 25-11-2019
  • Ўқишлар сони 0
  • Нашр санаси 10-07-2019
  • Мақола тилиRus
  • Саҳифалар сони36-42
Русский

Любые общие механизмы при РАС и желудочно-кишечных заболеваний не предлагаются в публикациях, поэтому последнее упоминание может быть предрасполагающим фактором. Предыдущие исследования при РАС, в принципе, предположили клеточно-опосредованную активацию иммунного ответа - распространенную для слизистой оболочки, оно имеет патогенетический смысл, но рано интерпретировать это как этиологию. Используются различные методы лечения, но терапия не является окончательной при РАС. Системные препараты можно попробовать, если местная терапия неэффективна. На самом деле этиология и патогенез рецидивирующего афтозного стоматита актуальна

English

Any common mechanisms for RAS and gastrointestinal diseases are not proposed in publications, that is why, last-mention may be predisposes factors. Previous studies at RAS, in principle, have suggested cellmediated activation of immune response – common for mucosa, they have pathogenetic and reactive meaning, but it is early to interpret that as an etiology. Various treatment modalities are used, but no therapy is definitive at RAS. Systemic medications can be tried if topical therapy is ineffective. Ethiology and pathogenesis of recurrent aphthous stomatitis still actually.

№ Муаллифнинг исми Лавозими Ташкилот номи
1 HASANOVA L.E.
2 AKHMEDOV A..
№ Ҳавола номи
1 1. McCullough, M. J., Abdel‐Hafeth, S., & Scully, C. (2007). Recurrent aphthous stomatitis revisited; clinical features, associations, and new association with infant feeding practices?.Journal of Oral Pathology & Medicine, 36(10), 615-620.
2 2. Zabolotko, V.M. Protocols of medical aid on a specialty «Pediatric therapeutic dentistry». The normative production and practical edition.-2013.-236 p
3 3. Brailo, V., Boras, V. V., & Cekić-Arambasin, A. (2007). Recurrent aphthous ulcerations: analysis of predisposing factors in 68 patients. Lijecnicki vjesnik, 129(1-2), 4-7.
4 4. Karaca, S., Seyhan, M., Senol, M., Harputluoglu, M. M., & Ozcan, A. (2008). The effect of gastric Helicobacter pylori eradication on recurrent aphthous stomatitis. International journal of dermatology,47(6), 615-617.
5 5. Piskin, S., Sayan, C., Durukan, N., & Senol, M. (2002). Serum iron, ferritin, folic acid, and vitamin B12 levels in recurrent aphthous stomatitis. Journal of the European Academy of Dermatology and Venereology, 16(1), 66-67.
6 6. Burgan, S. Z., Sawair, F. A., & Amarin, Z. O. (2006). Hematologic status in patients with recurrent aphthous stomatitis in Jordan.Saudi medical journal, 27(3), 381-384.
7 7. Barnadas, M. A., Remacha, A., & Condomines, J. (1997). Hematologic deficiencies in patients with recurrent oral aphthae.Medicina clinica, 109(3), 85-87.
8 8. Piskin, S., Sayan, C., Durukan, N., & Senol, M. (2002). Serum iron, ferritin, folic acid, and vitamin B12 levels in recurrent aphthous stomatitis. Journal of the European Academy of Dermatology and Venereology, 16(1), 66-67.
9 9. Masalha, R., Rudoy, I., Volkov, I., Yusuf, N., Wirguin, I., & Herishana, Y. (2002). Symptomatic dietary vitamin B deficiency in a nonvegetarian population. Am J Med, 112, 413-416.
10 10. Scully, C., Gorsky, M., & Lozada-Nur, F. (2003). The diagnosis and management of recurrent aphthous stomatitis: a consensus approach. The Journal of the American Dental Association, 134(2), 200-207.
11 11. Koybasi, S., Parlak, A. H., Serin, E., Yilmaz, F., & Serin, D. (2006). Recurrent aphthous stomatitis: investigation of possible etiologic factors. American journal of otolaryngology, 27(4), 229-232.
12 12. García, M. J., Baldellou, A. V., Calvo, M. M., Perez-Lungmus, G., & López, J. P. (2008, July). Hereditary juvenile cobalamin deficiency due to mutations in GIF gene. In Anales de Pediatria (Barcelona, Spain: 2003) (Vol. 69, No. 1, pp. 56-58).
13 13. Tanner, S. M., Li, Z., Bisson, R., Acar, C., Öner, C., Öner, R., ... & Krahe, R. (2004). Genetically heterogeneous selective intestinal malabsorption of vitamin B12: founder effects, consanguinity, and high clinical awareness explain aggregations in Scandinavia and the Middle East. Human mutation, 23(4), 327-333.
14 14. Aminoff, M., Carter, J. E., Chadwick, R. B., Johnson, C., Gräsbeck, R., Abdelaal, M. A., ... & de la Chapelle, A. (1999). Mutations in CUBN, encoding the intrinsic factor-vitamin B 12 receptor, cubilin, cause hereditary megaloblastic anaemia 1.Nature genetics, 21(3), 309.
15 15. Bouchlaka, C., Maktouf, C., Mahjoub, B., Ayadi, A., Sfar, M. T., Sioud, M., ... & Dellagi, K. (2007). Genetic heterogeneity of megaloblastic anaemia type 1 in Tunisian patients. Journal of human genetics, 52(3), 262.
16 16. Fedosov, S. N., Fedosova, N. U., Berglund, L., Moestrup, S. K., Nexø, E., & Petersen, T. E. (2005). Composite organization of the cobalamin binding and cubilin recognition sites of intrinsic factor.Biochemistry, 44(9), 3604-3614.
17 17. Kozyraki, R., & Gofflot, F. (2007). Multiligand endocytosis and congenital defects: roles of cubilin, megalin and amnionless.Current pharmaceutical design, 13(29), 3038-3046.
18 18. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Hebert, L. E., Scherr, P. A., & Schneider, J. A. (2005). Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Archives of neurology, 62(4), 641-645.
19 19. Marchini, L., Campos, M. S., Silva, A. M., Paulino, L. C., & Nobrega, F. G. (2007). Bacterial diversity in aphthous ulcers. Oral microbiology and immunology, 22(4), 225-231.
20 20. Albanidou-Farmaki, E., Poulopoulos, A. K., Epivatianos, A., Farmakis, K., Karamouzis, M., & Antoniades, D. (2008). Increased anxiety level and high salivary and serum cortisol concentrations in patients with recurrent aphthous stomatitis. The Tohoku journal of experimental medicine, 214(4), 291-296
21 21. Sun, A., Chu, C. T., Liu, B. Y., Wang, J. T., Leu, J. S., & Chiang, C. P. (2000). Expression of interleukin-2 receptor by activated peripheral blood lymphocytes upregulated by the plasma level of interleukin-2 in patients with recurrent aphthous ulcers.Proceedings of the National Science Council, Republic of China. Part B, Life sciences, 24(3), 116-122.
22 22. Savage, N. W., Mahanonda, R., Seymour, G. J., Bryson, G. J., & Collins, R. J. (1988). The proportion of suppressor‐inducer T‐lymphocytes is reduced in recurrent aphthous stomatitis. Journal of Oral Pathology & Medicine, 17(6), 293-297.
23 23. Stenman, G., & Heyden, G. (1980). Premonitory stages of recurrent aphthous stomatitis: I. Histological and enzyme histochemical investigations. Journal of Oral Pathology & Medicine,9(3), 155-162.
24 24. Poulter, L. W., & Lehner, T. (1989). Immunohistology of oral lesions from patients with recurrent oral ulcers and Behcet’s syndrome. Clinical and experimental immunology, 78(2), 189
25 25. Häyrinen‐Immonen, R. (1992). Immune‐activation in recurrent oral ulcers (ROU). European Journal of Oral Sciences, 100(4), 222-227.
26 26. Wray, D., Graykowski, E. A., & Notkins, A. L. (1981). Role of mucosal injury in initiating recurrent aphthous stomatitis. Br Med J (Clin Res Ed), 283(6306), 1569-1570.
27 27. Seder, R. A., & Paul, W. E. (1994). Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annual review of immunology, 12(1), 635-673.
28 28. Buno, I. J., Huff, J. C., Weston, W. L., Cook, D. T., & Brice, S. L. (1998). Elevated levels of interferon gamma, tumor necrosis factor α, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Archives of dermatology, 134(7), 827-831.
29 29. Lewkowicz, N., Lewkowicz, P., Banasik, M., Kurnatowska, A., & Tchórzewski, H. (2005). Predominance of type 1 cytokines and decreased number of CD4+ CD25+ high T regulatory cells in peripheral blood of patients with recurrent aphthous ulcerations.Immunology letters, 99(1), 57-62.
30 30. Lewkowicz, N., Lewkowicz, P., Dzitko, K., Kur, B., Tarkowski, M., Kurnatowska, A., & Tchórzewski, H. (2008). Dysfunction of CD4+ CD25high T regulatory cells in patients with recurrent aphthous stomatitis. Journal of oral pathology & medicine, 37(8), 454-461.
31 31. Albanidou-Farmaki, E., Markopoulos, A. K., Kalogerakou, F., & Antoniades, D. Z. (2007). Detection, enumeration and characterization of T helper cells secreting type 1 and type 2 cytokines in patients with recurrent aphthous stomatitis. The Tohoku journal of experimental medicine, 212(2), 101-105.
32 hthous ulceration. Clinical immunology and immunopathology, 72(1), 98-104.
33 32. Pedersen, A., & Ryder, L. P. (1994). γδ T-cell fraction of peripheral blood is increased in recurrent aphthous ulceration. Clinical immunology and immunopathology, 72(1), 98-104
34 33. Kaidashev, IP, Shinkevich, VI, & King, DM (2008). Essays on the immunobiology of the oral mucosa. Poltava: Polymet.-2008.-304 p.
35 34. Fortune, F., Walker, J., & Lehner, T. (1990). The expression of γΔ T cell receptor and the prevalence of primed, activated and IgA‐bound T cells in Behçet’s syndrome. Clinical & Experimental Immunology, 82(2), 326-332
36 35. Freysdottir, J., Lau, S. H., & Fortune, F. (1999). γδ T cells in Behçet’s disease (BD) and recurrent aphthous stomatitis (RAS).Clinical and experimental immunology, 118(3), 451.
37 36. Ben-Aryeh, H., Malberger, E., Gutman, D., Szargel, R., & Anavi, Y. (1976). Salivary IgA and serum IgG and IgA in recurrent aphthous stomatitis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 42(6), 746-752
38 37. de Oliveira Martinez, K., Mendes, L. L., & Alves, J. B. (2007). Secretory A immunoglobulin, total proteins and salivary flow in Recurrent Aphthous Ulceration. Brazilian journal of otorhinolaryngology, 73(3), 323-328
39 38. Bagg, J., Williams, B. D., Amos, N., Dagalis, P., & Walker, D. M. (1987). Absence of circulating IgG immune complexes in minor recurrent aphthous ulceration. Journal of Oral Pathology & Medicine, 16(2), 53- 56.
40 39. Natah, S. S., Häyrinen‐Immonen, R., Hietanen, J., Malmström, M., & Konttinen, Y. T. (2000). Immunolocalization of tumor necrosis factor‐α expressing cells in recurrent aphthous ulcer lesions (RAU). Journal of oral pathology & medicine, 29(1), 19-25.
41 40. Yasui, K., Kobayashi, N., Yamazaki, T., & Agematsu, K. (2005). Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Current pharmaceutical design,11(3), 395-401.
42 41. Thornhill, M. H., Baccaglini, L., Theaker, E., & Pemberton, M. N. (2007). A randomized, doubleblind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis.Archives of dermatology, 143(4), 463-470.
43 42. Sharma, N. L., Sharma, V. C., Mahajan, V. K., Shanker, V., Ranjan, N., & Gupta, M. (2007). Thalidomide: an experience in therapeutic outcome and adverse reactions. Journal of Dermatological Treatment, 18(6), 335- 340.
44 43. Sun, A., Chia, J. S., Wang, W. B., & Chiang, C. P. (2005). « Tien-Hsien liquid» can modulate antigenstimulated cytokine production by T-cells isolated from patients with recurrent aphthous ulcerations. The American journal of Chinese medicine, 33(04), 559-571.
45 44. Zribi, H., Crickx, B., & Descamps, V. (2007). Prevention of recurrent aphthous stomatitis by efalizumab (Raptiva®). Journal of the European Academy of Dermatology and Venereology, 21(9), 1286-1287.
46 45. Woodside, D. G., & Vanderslice, P. (2008). Cell Adhesion Antagonists. BioDrugs, 22(2), 85-100.
47 46. Matsuda, T., Ohno, S., Hirohata, S., Miyanaga, Y., Ujihara, H., Inaba, G., ... & Mizushima, Y. (2003). Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet’s disease. Drugs in R & D, 4(1), 19-28.
48 47. Lee, J. H., Jung, J. Y., & Bang, D. (2008). The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet’s disease. Journal of the European Academy of Dermatology and Venereology, 22(5), 590-595.
49 48. Rabinovich, I.M. (2000). Experience of using the drug «Imudon» in the treatment of diseases of the oral mucosa. Dentistry for all, (3), 10.
50 49. Tkachenko, P.I., Lohmatova, N.M., Shinkevich, V.I., Kaidashev, I.P., Tkachenko, P.I., Lohmatova, N.M., ... & Kaidashev, I.I. P. (2004). Clinical and immunological substantiation of the differentiated approach to the treatment of chronic generalized catarrhal gingivitis in children.
Кутилмоқда